Please use this identifier to cite or link to this item: https://doi.org/10.1007/s00417-016-3333-y
DC FieldValue
dc.titleEVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study
dc.contributor.authorTan, C.S
dc.contributor.authorNgo, W.K
dc.contributor.authorLim, L.W
dc.contributor.authorTan, N.W
dc.contributor.authorLim, T.H
dc.contributor.authoron behalf of the EVEREST Study Group
dc.date.accessioned2020-10-23T02:44:59Z
dc.date.available2020-10-23T02:44:59Z
dc.date.issued2016
dc.identifier.citationTan, C.S, Ngo, W.K, Lim, L.W, Tan, N.W, Lim, T.H, on behalf of the EVEREST Study Group (2016). EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study. Graefe's Archive for Clinical and Experimental Ophthalmology 254 (10) : 1923-1930. ScholarBank@NUS Repository. https://doi.org/10.1007/s00417-016-3333-y
dc.identifier.issn0721-832X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/179289
dc.description.abstractPurpose: To describe screening failures in the EVEREST study by examining the imaging characteristics that enabled differentiation of polypoidal choroidal vasculopathy (PCV) from cases that were subsequently diagnosed not to be PCV. Methods: Post-hoc analysis of 34 patients with PCV reported as screening failures from EVEREST study. Standardised confocal scanning laser indocyanine green angiography (ICGA) images were graded by the Central Reading Centre to confirm PCV diagnosis based on the presence of early focal sub-retinal hyperfluorescence on ICGA and at least one of the following six diagnostic criteria: (1) nodular appearance of polyp(s) on stereoscopic examination, (2) hypofluorescent halo around nodule(s), (3) presence of a branching vascular network, (4) pulsation of polyp(s) on dynamic ICGA, (5) orange sub-retinal nodules on colour fundus photography, or (6) massive sub-macular haemorrhage (4 disc areas in size). Additional detailed image grading was performed with stereo-imaging and dynamic early-phase ICGA. Results: Of the 95 screened PCV cases, 34 were excluded: (1) cases not suitable for recruitment as per the study protocol (n = 14), (2) equivocal lesions on ICGA characterised by small hyperfluorescent dots (n = 9), and (3) cases that were definitely not PCV (non-PCV, n = 11), identified by definitive diagnoses which included one case each of micro-aneurysm, retinal angiomatous proliferation, retino-choroidal anastomosis, small type-2 choroidal neovascularisation, retinal pigment epithelial (RPE) window defect and disciform scar; two cases of lesions where the choroidal vessel changed its course; and three cases of late-onset RPE staining. Conclusions: Standardised image grading techniques used in EVEREST study enabled effective differentiation of non-PCV from actual PCV. © 2016, The Author(s).
dc.publisherSpringer Verlag
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectadult
dc.subjectage related macular degeneration
dc.subjectaged
dc.subjectangioma
dc.subjectArticle
dc.subjectclinical article
dc.subjectdiagnostic error
dc.subjectfemale
dc.subjecthuman
dc.subjectindocyanine green angiography
dc.subjectmale
dc.subjectmicroaneurysm
dc.subjectmiddle aged
dc.subjectmulticenter study (topic)
dc.subjectphase 4 clinical trial (topic)
dc.subjectpolypoidal choroidal vasculopathy
dc.subjectpriority journal
dc.subjectrandomized controlled trial (topic)
dc.subjectretina detachment
dc.subjectretinal angiomatous proliferation
dc.subjectsubretinal neovascularization
dc.subjectvery elderly
dc.subjectyoung adult
dc.subjectadolescent
dc.subjectantagonists and inhibitors
dc.subjectChoroidal Neovascularization
dc.subjectclinical trial
dc.subjectcontrolled study
dc.subjectdouble blind procedure
dc.subjectfluorescence angiography
dc.subjectmacular degeneration
dc.subjectmulticenter study
dc.subjectphase 4 clinical trial
dc.subjectphotochemotherapy
dc.subjectPolyps
dc.subjectrandomized controlled trial
dc.subjectangiogenesis inhibitor
dc.subjectcoloring agent
dc.subjectindocyanine green
dc.subjectporphyrin
dc.subjectranibizumab
dc.subjectvasculotropin A
dc.subjectVEGFA protein, human
dc.subjectverteporfin
dc.subjectAdolescent
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAngiogenesis Inhibitors
dc.subjectChoroidal Neovascularization
dc.subjectColoring Agents
dc.subjectDiagnostic Errors
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectFluorescein Angiography
dc.subjectHumans
dc.subjectIndocyanine Green
dc.subjectMacular Degeneration
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPhotochemotherapy
dc.subjectPolyps
dc.subjectPorphyrins
dc.subjectRanibizumab
dc.subjectVascular Endothelial Growth Factor A
dc.typeArticle
dc.contributor.departmentOPHTHALMOLOGY
dc.description.doi10.1007/s00417-016-3333-y
dc.description.sourcetitleGraefe's Archive for Clinical and Experimental Ophthalmology
dc.description.volume254
dc.description.issue10
dc.description.page1923-1930
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s00417-016-3333-y.pdf1.18 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons